In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity. Note: Beyond what is publicly available today, several studies from established research groups showing substantial anti-addictive effects have been submitted to journals and will be published in mid-2024
Various mechanisms may underlie the inhibitory effect of melatonin on tau hyperphosphorylation, as depicted in Fig
Most people will benefit from a treatment that can fit with their lifestyle, so there's ongoing research into widening the range of treatment options." 3 | To learn how GLP-1 agonists can help with other health problems It's possible that GLP-1 therapies can also improve other health problems beyond diabetes and obesity such as kidney disease, and heart disease
For this reason, findings should be interpreted according to the evidence available for each individual peptide rather than assumed to apply directly to the blend
Make sure to avoid direct light and quick temperature shifts so the peptide bonds do not degrade early
If you missed our introduction to the Miami-based innovators behind some of the industry's most trusted ingredients, catch up in the article linked above to understand the pharmaceutical-grade approach that's reshaping nutraceutical delivery systems
